CN105726998A - Preparation method of medicine for treating posthepatitic syndrome - Google Patents
Preparation method of medicine for treating posthepatitic syndrome Download PDFInfo
- Publication number
- CN105726998A CN105726998A CN201610148491.3A CN201610148491A CN105726998A CN 105726998 A CN105726998 A CN 105726998A CN 201610148491 A CN201610148491 A CN 201610148491A CN 105726998 A CN105726998 A CN 105726998A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- herba
- medicine
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 241001656875 Sarcococca ruscifolia Species 0.000 claims abstract description 14
- 241001604597 Pyrestini Species 0.000 claims abstract description 12
- 239000000706 filtrate Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 241000533849 Gleditsia Species 0.000 claims description 12
- 238000011282 treatment Methods 0.000 abstract description 18
- 235000013399 edible fruits Nutrition 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 241000407826 Amblystegium serpens Species 0.000 abstract description 2
- 240000004244 Cucurbita moschata Species 0.000 abstract description 2
- 235000009854 Cucurbita moschata Nutrition 0.000 abstract description 2
- 240000000249 Morus alba Species 0.000 abstract description 2
- 235000008708 Morus alba Nutrition 0.000 abstract description 2
- 235000000832 Ayote Nutrition 0.000 abstract 1
- 241001448413 Chlorophytum laxum Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 abstract 1
- 240000002373 Ficus pumila Species 0.000 abstract 1
- 235000006718 Ficus pumila Nutrition 0.000 abstract 1
- 241000305491 Gastrodia elata Species 0.000 abstract 1
- 244000230012 Gleditsia triacanthos Species 0.000 abstract 1
- 235000013813 Gleditsia triacanthos Nutrition 0.000 abstract 1
- 241000488974 Loranthus Species 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 230000003071 parasitic effect Effects 0.000 abstract 1
- 235000015136 pumpkin Nutrition 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 22
- 208000006454 hepatitis Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 206010019799 Hepatitis viral Diseases 0.000 description 7
- 239000003172 expectorant agent Substances 0.000 description 7
- 230000003419 expectorant effect Effects 0.000 description 7
- 231100000283 hepatitis Toxicity 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 201000011392 Pallister-Hall syndrome Diseases 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 201000001862 viral hepatitis Diseases 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 230000002567 autonomic effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- JBDOSUUXMYMWQH-UHFFFAOYSA-N 1-naphthyl isothiocyanate Chemical compound C1=CC=C2C(N=C=S)=CC=CC2=C1 JBDOSUUXMYMWQH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000218231 Moraceae Species 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010059193 Acute hepatitis B Diseases 0.000 description 1
- 206010065051 Acute hepatitis C Diseases 0.000 description 1
- 241000512198 Amblystegiaceae Species 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 244000070010 Erythrina variegata Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000001549 Ipomoea eriocarpa Species 0.000 description 1
- 241000221040 Loranthaceae Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 241000167696 Prenanthes Species 0.000 description 1
- 241001547453 Sarcococca Species 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 241000316341 Taxillus chinensis Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 1
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/10—Bryophyta (mosses)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of medicine for treating posthepatitic syndrome, so as to solve the treatment problem of the posthepatitic syndrome.The preparation method is characterized by decocting 10-30 parts of sarcococca ruscifolia stapf, 6-12 parts of pumpkin vines, 3-10 parts of chlorophytum laxum, 6-12 parts of honeylocust, 3-10 parts of gastrodiaelata fruit, 6-12 parts of herba ipomoeae pescarpae, 6-12 parts of cortex erythrinae orientalis, 6-12 parts of ficus pumila, 6-12 parts of cassiabarktree fruit, 1-5 parts of amblystegium serpens, 3-10 parts of mulberry, and 10-25 parts of parasitic loranthus with water, filtering after 30 minutes to obtain filtrate, decocting dregs another 20 minutes to obtain filtrate, and mixing filtrate obtained at two steps.It has been clinically proven that the medicine for treating posthepatitic syndrome has the advantages of excellence curative effect and high safety, is worthy of clinic application and popularization.
Description
Technical field
The present invention is the divisional application of application for a patent for invention " a kind of capsule for convalescent period hepatitis syndrome " (2014101114781), relates to the field of Chinese medicines, is specifically related to a kind of preparation method treating posthepatitic syndrome medicine.
Background technology
Posthepatitic syndrome (Post-HepatitisSyndrome, PHS) is the syndrome being feature with autonomic nervous dysfunction occurred after being healed by viral hepatitis, also referred to as convalescent period hepatitis syndrome (ConvalescentHepatitisSyndrome).Owing to primary disease is the functional change occurred after hepatitis, do not have and positive check that result supports the evidence that inflammation exists, so clinical at present is only that inference is relevant with autonomic nervous dysfunction after hepatitis healing for this pathogenetic reason.
The treatment of PHS is the difficult point of liver disease always, often only by taking to carry out passive anti symptom treatment for autonomic nervous dysfunction, as selected the medicines such as vitamin B group, vitamin C, oryzanol, Radix Et Caulis Acanthopanacis Senticosi, but owing to the relation of this disease Yu autonomic nervous dysfunction is only inference, as other functional diseases, this kind of passive treatment effective percentage is only between 55 ~ 80%, even requiring over for patient with severe symptoms and use the mode of downern could control symptom.
Tcm clinical practice there is no posthepatitic syndrome name of disease, the treatment of hepatopathy deficiency syndrome is continued to use in treatment more, dialectical for stagnation of liver-QI with deficiency of the spleen, the rule for the treatment of is based on dispersing the stagnated live-QI to relieve the stagnation of QI, invigorating the spleen and benefiting QI, medicine many selections Radix Bupleuri, the Rhizoma Atractylodis Macrocephalae, Poria, Cortex Magnoliae Officinalis, Fructus Aurantii, stir-fry paddy Fructus Hordei Germinatus, RHIIZOMA DIOSCOREAE fr0m Henan of China, Radix Adenophorae (Radix Glehniae), Radix Ophiopogonis.But clinical practice is really not so, PHS occurs after acute viral hepatitis, occurs that the situation of liver spleen all void is actually rare.Treatment premised on qi-restoratives, causes that effective percentage is not high, and onset is slow.
Summary of the invention
The technical assignment of the present invention is for above the deficiencies in the prior art, it is provided that the preparation method of the treatment posthepatitic syndrome medicine that a kind of curative effect is affirmed and side effect is little.
This invention address that the technical scheme of its technical problem is: a kind of preparation method treating posthepatitic syndrome medicine, it is characterized in that: by Sarcococca ruscifolia Stapf 10 ~ 30 parts, Caulis Cucurbitae 6 ~ 12 parts, Herba Chlorophyti Laxi 3 ~ 10 parts, 6 ~ 12 parts of Fructus Gleditsia, go back 3 ~ 10 parts of bobbin, Herba Ipomoeae Pes-Capraes 6 ~ 12 parts, Cortex erythrinae 6 ~ 12 parts, Caulis fici pumilae (Fructus Fici Pumilae) 6 ~ 12 parts, Fructus cinnamomi immaturus 6 ~ 12 parts, Folium Salicis Babylonicae moss 1 ~ 5 part, Fructus Mori 3 ~ 10 parts, 10 ~ 25 parts of mixing and water addings decoctions of Herba Taxilli, filtrate is taken after 30 minutes, medicinal residues add water after continuation decocts 20 minutes and take filtrate, and twice filtrate merges.
Wherein said: Sarcococca ruscifolia Stapf, for Buxaceae Sarcococca plant fragrance osmanthus SarcococcaruscifoliaStapf root.Nature and flavor are pungent, bitter, flat.Merit can regulating QI to relieve pain, dispelling, collateral-activating.
Caulis Cucurbitae, for the stem of cucurbitaceous plant Fructus Cucurbitae moschatae Cucurbitamoschata (Duch.ExLam.) Duch.ExPoir..Sweet-bitter flavor, cold nature is nontoxic.Enter liver, spleen two warp.Merit can lung heat clearing, stomach function regulating, dredging collateral.
Herba Chlorophyti Laxi, for herb or the root of feverfew Prenanthes henryi Dunn PrenantheshenryiDunn.Bitter in the mouth；Cold in nature.Merit can heat-clearing and toxic substances removing；Dissipating blood stasis stops blooding.
Fructus Gleditsia, for the fruit of leguminous plant Fructus Gleditsia GleditsiasinensisLam..Nature and flavor are pungent, temperature.Return lung；Large intestine channel.Merit can expelling phlegm for arresting cough；Have one's ideas straightened out to lead to and close；Parasite killing eliminating stagnation.
Also bobbin, for the fruit of orchid Rhizoma Gastrodiae GastrodiaelataBl..Sweet in the mouth；Cold in nature.Merit can qi-restoratives subduing the wind syndrome.
Herba Ipomoeae Pes-Capraes, for Convolvulaceae morning glory two leaf Radix Ipomoeae Ipomoeapescarpae(L.) herb of Sweet.Nature and flavor hardship pungent, micro-, wet.Merit can expelling wind and removing dampness, detumescence of drawing out pus by applying a plaster to the affected part.
Cortex erythrinae, for bark or the root bark of pulse family Erythrinae Arborescentis ErythrinaindicaLam..Nature and flavor are bitter, flat.Return liver, kidney channel.Merit can wind-damp dispelling, channels sootheing and network vessel quickening.Wind-damp dispelling, the meridian dredging, parasite killing.
Caulis fici pumilae (Fructus Fici Pumilae), for the stem of moraceae plants Caulis fici pumilae (Fructus Fici Pumilae) FicuspumilaL., leaf.Sour in the mouth, cool in nature.Merit can expelling wind and removing dampness；Promoting blood circulation to remove obstruction in the collateral；Removing toxic substances and promoting subsidence of swelling.
Fructus cinnamomi immaturus, for the tender fruit of children of canella Cortex Cinnamomi.Gas fragrance, taste is micro-sweet.Nature and flavor Wen Xingan, returns stomach warp.Merit can warming spleen and stomach for dispelling cold.
Folium Salicis Babylonicae moss, for Amblystegiaceae Folium Salicis Babylonicae moss Amblystegiumserpens(Hedw.) plant of B.S.G..Nature and flavor are puckery；Flat.Merit can astringing to arrest bleeding.
Fructus Mori, for the dry fruit ear of moraceae plants Mulberry MorusalbaL..Nature and flavor are sweet, sour, cold.GUIXIN, liver, kidney channel.Merit can be enriched blood YIN nourishing, promotes the production of body fluid and moisturizes.
Herba Taxilli, is Loranthaceae plant Herba Taxilli Taxilluschinensis(DC. for Herba Taxilli) the dry stem and branch with leaf of Danser.Nature and flavor bitter, sweet, flat.Return liver, kidney channel.Merit can invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive unit.
Composition principle: tcm clinical practice there is no posthepatitic syndrome name of disease, the treatment of hepatopathy deficiency syndrome is continued to use in treatment more, dialectical for stagnation of liver-QI with deficiency of the spleen, the rule for the treatment of is based on dispersing the stagnated live-QI to relieve the stagnation of QI, invigorating the spleen and benefiting QI, medicine many selections Radix Bupleuri, the Rhizoma Atractylodis Macrocephalae, Poria, Cortex Magnoliae Officinalis, Fructus Aurantii, stir-fry paddy Fructus Hordei Germinatus, RHIIZOMA DIOSCOREAE fr0m Henan of China, Radix Adenophorae (Radix Glehniae), Radix Ophiopogonis.But clinical practice is really not so, PHS occurs after acute viral hepatitis, namely (symptom of digestive tract disappears after viral hepatitis healing, liver size and liver function recovery or close normal), still there is viral hepatitis Symptoms in persistence, the sustainable several months is to the several years, and row liver biopsy pathology checks discovery without exception.Acute viral hepatitis is often fallen ill hurried, does not injure vigour and occurs that the situation of liver spleen all void is actually rare.Its hepatitis symptom shows, and description 3 is only the obstructed performance of liver network in fact.Treatment premised on qi-restoratives, effective percentage is not high, and onset is slow.Inventor is clinical experience gained for many years: posthepatitic syndrome is relevant with there being the expectorant smouldered in liver network, and the medicine owing to treating hepatitis is mostly cold and cool, coagulates with expectorant so cold, depressed liver network, causes that liver network does not relax, and rise vexed discomfort in local.Even if being dredged by force by soothing the liver medicines such as Radix Bupleuri, but the solidifying local of expectorant, phlegm and blood stasis, and glue work is suffer from, protracted course of disease.
Compared with prior art, the invention have the characteristics that:
1, prescription is unique: take Sarcococca ruscifolia Stapf in side, Caulis Cucurbitae is monarch, the combination of both described Sarcococca ruscifolia Stapf and Caulis Cucurbitae can suppressing the hyperactive liver and easing the stomach, the meridian dredging, profit blood vessels, and blood nourishes blood, regulating menstruation is regulated the flow of vital energy, and it is characterized in that Papillary can go liver network wind-phlegm of being possessed to coagulate.Inventor's laboratory pharmacological research shows: heavy dose of Sarcococca ruscifolia Stapf decoct rat oral gavage (1000mg/kg), it is possible to the rat liver homogenate lipid peroxidation of antagonism FeC12-vitamin C-ADP mixture induction, makes malonaldehyde (MDA) content decline；Caulis Cucurbitae extract lumbar injection, the rats'liver that α-naphthyl isothiocyanate (ANIT) is caused infringement has inhibitory action, can suppress the increase of serum bilirubin.And MDA is clearly relevant with PHS class hepatitis symptom to increasing of serum bilirubin.
2, take Herba Chlorophyti Laxi, Fructus Gleditsia, go back bobbin in side, Herba Ipomoeae Pes-Capraes is minister: PHS liver network expectorant coagulates, and expectorant stasis of blood reciprocal causation, therefore choose Herba Chlorophyti Laxi removing toxic substances dissipating blood stasis；Monarch drug dredging collateral power is strong, eliminates the phlegm turbid not sufficiently effective, therefore takes Fructus Gleditsia expectorant powder junction；The basis of expectorant is that water is turbid, therefore takes Herba Ipomoeae Pes-Capraes dehumidifying；Also there is the merit of open-minded deficiency-phlegm among bobbin and we.
3, supplementary drug thing: Cortex erythrinae treatment of arthritis and promoting collateral and channels, and contribute to the suppression of hepatitis virus；Caulis fici pumilae (Fructus Fici Pumilae) helps Herba Chlorophyti Laxi removing toxic substances dissipating blood stasis；Fructus Mori, Herba Taxilli help goes back bobbin invigorating the liver and kidney, vital base and primordial QI consolidating；Fructus cinnamomi immaturus warming middle-JIAO, one sideization cold-phlegm, also there is the balanced property of medicine on the other hand, it is prevented that cold and cool meaning too.
4, take Folium Salicis Babylonicae moss using corrigent, take the meaning of its convergence.
5, medicine material consumption of the present invention is to grope summary in a large number through inventor to draw: Sarcococca ruscifolia Stapf dosage is heavier, the merit of this dosage replenishing blood and nourishing liver arranged below；Folium Salicis Babylonicae moss dosage is less, takes the meaning of its convergence using corrigent, without affecting the overall property of medicine of we's row liver network.
Detailed description of the invention
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: Sarcococca ruscifolia Stapf 20 parts, Caulis Cucurbitae 10 parts, Herba Chlorophyti Laxi 6 parts, 10 parts of Fructus Gleditsia, go back 6 parts of bobbin, Herba Ipomoeae Pes-Capraes 10 parts, Cortex erythrinae 10 parts, Caulis fici pumilae (Fructus Fici Pumilae) 10 parts, Fructus cinnamomi immaturus 10 parts, Folium Salicis Babylonicae moss 2 parts, Fructus Mori 6 parts, Herba Taxilli 20 parts.
The preparation method of embodiment 1 is: by Sarcococca ruscifolia Stapf, Caulis Cucurbitae, Herba Chlorophyti Laxi, Fructus Gleditsia, go back bobbin, Herba Ipomoeae Pes-Capraes, Cortex erythrinae, Caulis fici pumilae (Fructus Fici Pumilae), Fructus cinnamomi immaturus, Folium Salicis Babylonicae moss, Fructus Mori, the decoction of Herba Taxilli mixing and water adding, filtrate is taken after 30 minutes, medicinal residues add water after continuation decocts 20 minutes and take filtrate, twice filtrate merges, and is divided into two parts of morning and evenings and takes.
Embodiment 2, crude drug weight proportion: Sarcococca ruscifolia Stapf 10 parts, Caulis Cucurbitae 6 parts, Herba Chlorophyti Laxi 3 parts, 6 parts of Fructus Gleditsia, description 4 go back 3 parts of bobbin, Herba Ipomoeae Pes-Capraes 6 parts, Cortex erythrinae 6 parts, Caulis fici pumilae (Fructus Fici Pumilae) 6 parts, Fructus cinnamomi immaturus 6 parts, Folium Salicis Babylonicae moss 1 part, Fructus Mori 3 parts, Herba Taxilli 10 parts.
Embodiment 3, crude drug weight proportion: Sarcococca ruscifolia Stapf 20 parts, Caulis Cucurbitae 10 parts, Herba Chlorophyti Laxi 6 parts, 10 parts of Fructus Gleditsia, go back 6 parts of bobbin, Herba Ipomoeae Pes-Capraes 10 parts, Cortex erythrinae 10 parts, Caulis fici pumilae (Fructus Fici Pumilae) 10 parts, Fructus cinnamomi immaturus 10 parts, Folium Salicis Babylonicae moss 2 parts, Fructus Mori 6 parts, Herba Taxilli 20 parts.
Embodiment 4, crude drug weight proportion: Sarcococca ruscifolia Stapf 30 parts, Caulis Cucurbitae 12 parts, Herba Chlorophyti Laxi 10 parts, 12 parts of Fructus Gleditsia, go back 10 parts of bobbin, Herba Ipomoeae Pes-Capraes 12 parts, Cortex erythrinae 12 parts, Caulis fici pumilae (Fructus Fici Pumilae) 12 parts, Fructus cinnamomi immaturus 12 parts, Folium Salicis Babylonicae moss 5 parts, Fructus Mori 10 parts, Herba Taxilli 25 parts.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from as follows: (1) by Cortex erythrinae, Caulis Cucurbitae, go back bobbin, Herba Ipomoeae Pes-Capraes, Fructus cinnamomi immaturus, Caulis fici pumilae (Fructus Fici Pumilae) coarse powder respectively with vapor distillation extract volatile oil, and collect after mixing for standby use, medicinal residues are standby；(2) the medicinal residues mixing in Sarcococca ruscifolia Stapf, Herba Taxilli, Herba Chlorophyti Laxi, Fructus Gleditsia, Folium Salicis Babylonicae moss, Fructus Mori and step 1 is added 5 times of water yields, boiling 2 times, each 1 hour, collecting decoction, stand；Then the ethanol of the 95% of 3 ~ 4 times of medicinal liquids of addition in decocting liquid, stands 15 minutes, is then centrifuged 20 minutes with 3000rpm/min, takes supernatant, spray drying, draws just material；(3) gained volatile oil in step 1 is sprayed at the beginning of step 2 gained in material, mixing, cross 60 mesh sieves, encapsulated form.
Can set that every capsules is 0.5g.
The efficient combination of said medicine, coordinates mutually, effectively reaches the purpose for the treatment of posthepatitic syndrome, and side effect is less.The above results is that clinical data fully proves, relevant information is as follows.
1 object and method.
1.1 objects.
1.1.1 case selection: in March, 2011 ~ 2013 year diagnosis in March is posthepatitic syndrome 98 example, wherein male 70 example, women 28 example；Age 19 ~ 65(41.32 ± 12.71) year；The course of disease 3 months to 2 years, average (5.19 ± 1.72) moon；Wherein acute hepatitis A 22 example, acute hepatitis B 31 example, acute hepatitis C 21 example, acute hepatitis E 10 example, chronic hepatitis B 14 example.98 example patients are divided into matched group 34 example, decoction group 32 example and Capsules group 32 example, compare before three groups of patient treatments in sex, age, the state of an illness, the course of disease, no significant difference (P > 0.05), have comparability.
1.1.2 diagnosis basis: 1. adult patient history of virus hepatitis and healing；2. in a period of time after hepatitis is cured, tired, inappetence occur, feel sick, right epigastric discomfort, body weight can not recover standard to disease；3. just can touch under liver rib, or with tenderness；4. liver function is normal, but serum transaminase can once raise, and serum globulin is normal；5. the above-mentioned symptom sign that except, other reasons causes.
1.2 methods.
1.2.1 Therapeutic Method: matched group takes 2 times/d of placebo.Decoction group with gained decoction oral in the embodiment of the present invention 1,2 times/d.Capsules group with gained capsule oral in the embodiment of the present invention 3,2g/ time, 2 times/d.14d is a course for the treatment of.
1.2.2 criterion of therapeutical effect: recovery from illness: clinical symptoms, sign disappear, after half a year, weight recovery normally or increases；Effective: clinical symptoms, sign disappear, after half a year, body weight fails recover normal or increase；Effective: clinical symptoms, sign alleviate；Invalid: clinical symptoms, sign are unchanged.
1.2.3 statistical analysis: SPSS13.0 carries out statistical analysis.Measurement data t checks, enumeration data chi-square criterion.
2 result 2.1 3 groups Comprehensive Clinical comparitive study: see following table.
Decoction group and Capsules group cure rate, total effective rate are obviously higher than matched group (P < 0.01).
2.2 3 groups of adverse reactions of patients incidence rates compare: three groups obvious adverse reaction all do not occur.
2.3 3 groups of patients aobvious case in advance in 1 year recurrence compare: matched group relapse rate is 42.86%(3/7 example)；Decoction group 6.90%(2/29 example)；Capsules group 6.67%(2/30 example).Decoction group and Capsules group relapse rate are all significantly lower than matched group (P < 0.01).
3. this result of study of conclusion display, take the decoction group of the present invention and Capsules group total effective rate apparently higher than matched group, and without obvious adverse reaction, illustrate that pharmaceutical composition prepared by the inventive method has the advantage that definite effect, untoward reaction are relatively light, safety is higher in treatment posthepatitic syndrome.
Claims (1)
1. the preparation method treating posthepatitic syndrome medicine, it is characterized in that: by Sarcococca ruscifolia Stapf 10 ~ 30 parts, Caulis Cucurbitae 6 ~ 12 parts, Herba Chlorophyti Laxi 3 ~ 10 parts, 6 ~ 12 parts of Fructus Gleditsia, go back 3 ~ 10 parts of bobbin, Herba Ipomoeae Pes-Capraes 6 ~ 12 parts, Cortex erythrinae 6 ~ 12 parts, Caulis fici pumilae (Fructus Fici Pumilae) 6 ~ 12 parts, Fructus cinnamomi immaturus 6 ~ 12 parts, Folium Salicis Babylonicae moss 1 ~ 5 part, Fructus Mori 3 ~ 10 parts, 10 ~ 25 parts of mixing and water addings decoctions of Herba Taxilli, filtrate is taken after 30 minutes, medicinal residues add water after continuation decocts 20 minutes and take filtrate, and twice filtrate merges.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610148491.3A CN105726998A (en) | 2014-03-24 | 2014-03-24 | Preparation method of medicine for treating posthepatitic syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610148491.3A CN105726998A (en) | 2014-03-24 | 2014-03-24 | Preparation method of medicine for treating posthepatitic syndrome |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410111478.1A Division CN103830594B (en) | 2014-03-24 | 2014-03-24 | A kind of capsule for convalescence hepatitis syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105726998A true CN105726998A (en) | 2016-07-06 |
Family
ID=56251201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610148491.3A Withdrawn CN105726998A (en) | 2014-03-24 | 2014-03-24 | Preparation method of medicine for treating posthepatitic syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105726998A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032335A (en) * | 2007-04-17 | 2007-09-12 | 李永胜 | Compound health product for reducing blood sugar |
| CN101961433A (en) * | 2010-09-06 | 2011-02-02 | 肖玉芹 | Chinese medicinal decoction for treating neonate hepatitis syndrome |
| CN103223069A (en) * | 2013-05-20 | 2013-07-31 | 崔新明 | Traditional Chinese medicine composition for treating hepatitis |
| CN103301356A (en) * | 2013-07-01 | 2013-09-18 | 张庆焕 | Preparation method of enema for chronic renal failure |
| CN103550547A (en) * | 2013-10-25 | 2014-02-05 | 孙振玲 | Traditional Chinese medicine for treating posthepatitic syndrome |
-
2014
- 2014-03-24 CN CN201610148491.3A patent/CN105726998A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032335A (en) * | 2007-04-17 | 2007-09-12 | 李永胜 | Compound health product for reducing blood sugar |
| CN101961433A (en) * | 2010-09-06 | 2011-02-02 | 肖玉芹 | Chinese medicinal decoction for treating neonate hepatitis syndrome |
| CN103223069A (en) * | 2013-05-20 | 2013-07-31 | 崔新明 | Traditional Chinese medicine composition for treating hepatitis |
| CN103301356A (en) * | 2013-07-01 | 2013-09-18 | 张庆焕 | Preparation method of enema for chronic renal failure |
| CN103550547A (en) * | 2013-10-25 | 2014-02-05 | 孙振玲 | Traditional Chinese medicine for treating posthepatitic syndrome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104107349A (en) | Chinese herbal medicine for three-hypers patients, and its administration method | |
| CN101780223B (en) | Traditional Chinese medicine with integral coordination function for treating ischemic cerebrovascular disease | |
| CN103055116A (en) | Traditional Chinese medicine composition for treating acnes | |
| CN101130054A (en) | Traditional Chinese medicine for treating phlegm-turbidity internal-resistance type dizziness | |
| CN102988616B (en) | Chinese medicinal composition for treating anemia | |
| CN103550688B (en) | A kind of Chinese medicine composition for the treatment of cardiopalmus | |
| CN105079444A (en) | Traditional Chinese medicine composition for treating bronchial asthma | |
| CN104606514A (en) | Traditional Chinese medicine composition for treating kidney deficiency type tinnitus | |
| CN104623536A (en) | Chinese medicinal combination for treating insomnia | |
| CN104524479B (en) | A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof | |
| CN105963635A (en) | Traditional Chinese medicinal composition for treating headache | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN100998824A (en) | Oral Chinese medicine for treating virus myocarditis | |
| CN104173933A (en) | Traditional Chinese medicine composition for treating depressive disorder | |
| CN102423367B (en) | Beautifying and blood-activating medicament | |
| CN102988776A (en) | Traditional Chinese medicine composition for treating vertigo | |
| CN103830594B (en) | A kind of capsule for convalescence hepatitis syndrome | |
| CN105726998A (en) | Preparation method of medicine for treating posthepatitic syndrome | |
| CN102284023A (en) | Chinese medicinal composition for treating asthma | |
| CN106581553A (en) | Lozenge utilizing biological extract to treat cardio-cerebrovascular diseases and preparation method thereof | |
| CN100998720B (en) | Oral traditional Chinese medicine for treating amenorrhea of uterus stasis | |
| CN106466421A (en) | A kind of formula alleviating myopia symptom | |
| CN105456447A (en) | Folium artemisiae argyi-containing traditional Chinese medicine composition with function of promoting blood circulation to remove stasis and preparation method thereof | |
| CN105833152A (en) | Traditional Chinese medicine composition for treating endocrine dyscrasia | |
| CN105362999A (en) | Traditional Chinese medicine preparation for preventing and treating infantile repeated cold and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160706 |